Deepak Jayakumar, Pharmaceut Reg Affairs 2021, Volume 10

Deepak Jayakumar

Frost & Sullivan, India

Factors Dictating the Uptake and Success of the Third Wave of Biosimilars

The patent expiry of advanced biologics starting 2020 is set to bring about the potential launch of third wave biosimilars. There are going to be numerous patent expiries of advanced, valuable and life-saving biologics between 2020-2026 and the biopharmaceutical world is already gearing up with the development and commercialization of biosimilar version of the innovator drugs.

Traditionally, biosimilars have not enjoyed great market access in the initial years. While market access of the third wave biosimilars will still be dictated by the existing complex market dynamics such as the re-imbursement and the payer landscape, biosimilar pricing trends, and the various sales models, there are promising developments on the payer landscape in the developing regions which should enable better uptake of biosimilars. Further, regional differences will continue to play an important role in the market access of biosimilars as factors such as pricing, physicians' acceptance of biosimilars, manufacturing complexities, and patent litigations are expected to drive both the overall biosimilars market as well as the third wave biosimilars specifically. Another interesting development that will govern the uptake of third wave of biosimilars are increased biosimilar uptake in general, tackling manufacturing complexities, interchangeability status in the US, as well as the reception of biosimilars in newer therapy areas.

Biography

Deepak Jayakumar has completed his MS in Biotechnology from New York University. He is an Industry Analyst specializing in the Biopharmaceutical market with Frost & Sullivan, a premier research consulting organization. He has nearly 9 years of experience in the life sciences industry including 3+ years of experience consulting for pharmaceutical and healthcare companies in addition to experience in biosimilars manufacturing.